trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'breast']
 meaningful improvements in both progression free survival and overall survival but with notable rates of ild.
#asco22 #dbo4 trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm 
Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine